Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
1. Clearmind received IRB approval for CMND-100 trial at TASMC. 2. The trial aims to evaluate CMND-100 for Alcohol Use Disorder treatment. 3. Participation from esteemed institutions like Yale and Johns Hopkins enhances credibility. 4. The study assesses safety, tolerability, and efficacy for AUD patients. 5. AUD accounts for significant global mortality, highlighting urgent treatment needs.